Value of CT-Textural Features and Volume-Based PET Parameters in Comparison to Serologic Markers for Response Prediction in Patients with Diffuse Large B-Cell Lymphoma Undergoing CD19-CAR-T Cell Therapy.
chimeric antigen receptor T cells
computed tomography
diffuse-large B cell lymphoma
positron emission tomography
response assessment
texture analysis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 Mar 2022
10 Mar 2022
Historique:
received:
23
01
2022
revised:
07
03
2022
accepted:
08
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
The goal of this study was to investigate the value of CT-textural features and volume-based PET parameters in comparison to serologic markers for response prediction in patients with diffuse large B-cell lymphoma (DLBCL) undergoing cluster of differentiation (CD19)-chimeric antigen receptor (CAR)-T cell therapy. We retrospectively analyzed the whole-body (WB)-metabolic tumor volume (MTV), the WB-total lesion glycolysis (TLG) and first order textural features derived from 18F-FDG-PET/CT, as well as serologic parameters (C-reactive protein [CRP] and lactate dehydrogenase [LDH], leucocytes) prior and after CAR-T cell therapy in 21 patients with DLBCL (57.7 ± 14.7 year; 7 female). Interleukin 6 (IL-6) and IL-2 receptor peaks were monitored after treatment onset and compared with patient outcome judged by follow-up 18F-FDG-PET/CT. In 12/21 patients (57%), complete remission (CR) was observed, whereas 9/21 patients (43%) showed partial remission (PR). At baseline, WB-MTV and WB-TLG were lower in patients achieving CR (35 ± 38 mL and 319 ± 362) compared to patients achieving PR (88 ± 110 mL and 1487 ± 2254; p < 0.05). The “entropy” proved lower (1.81 ± 0.09) and “uniformity” higher (0.33 ± 0.02) in patients with CR compared to PR (2.08 ± 0.22 and 0.28 ± 0.47; p < 0.05). Patients achieving CR had lower levels of CRP, LDH and leucocytes at baseline compared to patients achieving PR (p < 0.05). In the entire cohort, WB-MTV and WB-TLG decreased after therapy onset (p < 0.01) becoming not measurable in the CR-group. Leucocytes and CRP significantly dropped after therapy (p < 0.01). The IL-6 and IL-2R peaks after therapy were lower in patients with CR compared to PR (p > 0.05). In conclusion, volume-based PET parameters derived from PET/CT and CT-textural features have the potential to predict therapy response in patients with DLBCL undergoing CAR-T cell therapy.
Identifiants
pubmed: 35329846
pii: jcm11061522
doi: 10.3390/jcm11061522
pmc: PMC8951429
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1417-1427
pubmed: 30941463
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Eur Radiol. 2020 Aug;30(8):4623-4632
pubmed: 32248365
Eur J Nucl Med Mol Imaging. 2018 May;45(5):699-711
pubmed: 29214417
Contrast Media Mol Imaging. 2020 Aug 21;2020:2981585
pubmed: 32922221
Nucl Med Commun. 2021 Jul 1;42(7):792-799
pubmed: 33741852
Hematology. 2016 Mar;21(2):99-105
pubmed: 26183456
Br J Haematol. 2016 Jan;172(2):246-54
pubmed: 26577576
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639
JACC Cardiovasc Imaging. 2019 Oct;12(10):1946-1954
pubmed: 30660549
PLoS One. 2015 May 04;10(5):e0124165
pubmed: 25938522
Invest Radiol. 2018 Jun;53(6):338-343
pubmed: 29420321
Oncotarget. 2016 Dec 13;7(50):83544-83553
pubmed: 27835875
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Immunol Med. 2021 Jun;44(2):69-73
pubmed: 32693699
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
Med Oncol. 2015 Jan;32(1):446
pubmed: 25511321
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Chin J Cancer Res. 2021 Oct 31;33(5):563-573
pubmed: 34815630
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
Ann Hematol. 2015 May;94(5):803-12
pubmed: 25501975